For the details of MPM ONCOLOGY IMPACT MANAGEMENT LP's stock buys and sells, go to https://www.gurufocus.com/guru/mpm+oncology+impact+management+lp/current-portfolio/portfolio
These are the top 5 holdings of MPM ONCOLOGY IMPACT MANAGEMENT LP- Harpoon Therapeutics Inc (HARP) - 3,898,422 shares, 35.39% of the total portfolio.
- Epizyme Inc (EPZM) - 2,331,534 shares, 28.35% of the total portfolio.
- G1 Therapeutics Inc (GTHX) - 1,423,794 shares, 12.30% of the total portfolio.
- Turning Point Therapeutics Inc (TPTX) - 308,686 shares, 10.81% of the total portfolio. New Position
- Y-mAbs Therapeutics Inc (YMAB) - 337,291 shares, 6.90% of the total portfolio.
Mpm Oncology Impact Management Lp initiated holding in Turning Point Therapeutics Inc. The purchase prices were between $32.02 and $66.17, with an estimated average price of $53.48. The stock is now traded at around $56.88. The impact to a portfolio due to this purchase was 10.81%. The holding were 308,686 shares as of .
Sold Out: Arqule Inc (ARQL)Mpm Oncology Impact Management Lp sold out a holding in Arqule Inc. The sale prices were between $19.96 and $20.04, with an estimated average price of $20.
Sold Out: Deciphera Pharmaceuticals Inc (DCPH)Mpm Oncology Impact Management Lp sold out a holding in Deciphera Pharmaceuticals Inc. The sale prices were between $33.63 and $69.4, with an estimated average price of $55.84.
Sold Out: argenx SE (ARGX)Mpm Oncology Impact Management Lp sold out a holding in argenx SE. The sale prices were between $108.83 and $165.23, with an estimated average price of $146.92.
Here is the complete portfolio of MPM ONCOLOGY IMPACT MANAGEMENT LP. Also check out:
1. MPM ONCOLOGY IMPACT MANAGEMENT LP's Undervalued Stocks
2. MPM ONCOLOGY IMPACT MANAGEMENT LP's Top Growth Companies, and
3. MPM ONCOLOGY IMPACT MANAGEMENT LP's High Yield stocks
4. Stocks that MPM ONCOLOGY IMPACT MANAGEMENT LP keeps buying